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S U M M A R Y
Objective: This study utilized genotypic and in-house recombinant virus phenotypic assays to examine
HIV-1 variant susceptibility to antiretroviral (ARV) drugs; comparisons were made between the
analyses.
Methods: A nested PCR was employed to amplify the HIV-1 gag-pol gene, which comprised the entire PR
gene (codons 1–99) and the former RT gene (codons 1–312). Genetic resistance was determined by
submitting the sequences to the Stanford University Network HIV-1 Database. Phenotypic susceptibili-
ties to six ARV drugs were measured using a high-throughput, multi-cycle, recombinant virus
phenotypic assay. Results were expressed in terms of the IC50 (half maximal inhibitory concentration)
and fold-change values. The relationship between phenotypic drug resistance and genetic polymor-
phisms was determined.
Results: Nineteen fragment sequences for which recombinant viruses were successfully constructed
were translated and compared with the consensus B sequences in the Stanford University Network HIV-
1 Database. No recognizable genotypic resistance-associated mutations were noted, except in one
sample. Each homologous replication-competent recombinant viral fold-change in the presence of six
ARV drugs used widely in China was measured. According to the clinical and statistical criteria, 16 of the
19 samples were susceptible to the six drugs tested. The majority of phenotypic and genotypic results
obtained were in agreement, with a concordance rate of 97.4%. Both phenotypic and genotypic assays
suggested that sample HN2009001 was resistant to all drugs tested. All phenotypic and genotypic results
obtained regarding the susceptibility of the 19 recombinant viruses to nucleoside reverse transcriptase
inhibitors (NRTIs) were in agreement. With regard to the genotypic results for the non-nucleoside
reverse transcriptase inhibitors (NNRTIs), 7.9% (3/38) were inconsistent with the phenotypic results.
Conclusions: The in-house recombinant virus phenotypic assay was able to provide a straightforward
quantitative assessment of resistance. In most cases, the genotypic and novel phenotypic assays yielded
similar results. The disparity in HIV-1 susceptibility indicates a need to further investigate the clinical
outcomes of antiretroviral therapy in certain individuals.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The ‘Four Frees and One Care’ policy was implemented in China
in 2003 for AIDS prevention and control. This policy includes free
antiretroviral treatment (ART) for AIDS patients. Since the* Corresponding authors.
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(W. Zhang).
http://dx.doi.org/10.1016/j.ijid.2015.06.011
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).implementation of this policy, the morbidity and mortality rates
attributable to HIV infection have declined signiﬁcantly.1,2
Unfortunately, many treated patients have developed resistance
to one or more drug classes, and this resistance can lead to
treatment failure and limitations in alternative treatment regi-
mens.3 Furthermore, these drug-resistant variants can be trans-
mitted to treatment-naı¨ve patients, thereby becoming a major ART
obstacle.4
The detection of resistance in treatment-naı¨ve and treatment-
experienced patients has become increasingly important for theirciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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resistance testing is of considerable value in many aspects. The
drug resistance assay is essential for the selection of the optimal
treatment regimen. Furthermore, HIV drug resistance testing is
also of beneﬁt for monitoring the spread of primary drug resistance
mutations, as well as the development of new antiretroviral (ARV)
drugs.
Two main types of drug resistance assay have been developed
and are available: genotypic resistance assays, which can detect
speciﬁc resistance-related mutations in the target viral genes, and
phenotypic resistance assays, which test the capacity of viral
replication or enzymatic activity in the presence of a particular
drug in vitro. In general, genotypic resistance testing is more
widely used than phenotypic resistance testing. This is mainly due
to the fact that sequencing is rapid, costs are relatively low, and
many genotypic interpretation algorithms are available online,
making the genotypic assay a preferred method for clinical
resistance testing.6 However, since many genotypic interpretation
algorithms depend on the knowledge acquired from phenotyping,
it is difﬁcult to interpret the sequences with unusual mutations or
complex combinations of mutation patterns;7 thus this should be
complemented by direct phenotyping.
The phenotypic drug susceptibility assay is able to provide
more direct quantitative resistance measurements for each ARV
agent, including US Food and Drug Administration (FDA)-approved
drugs and compounds under clinical evaluation. In addition, it can
be performed without any prior knowledge of mutations.
Traditional phenotypic assays that detect drug susceptibility of
clinical isolates have several limitations: they require fresh healthy
donor peripheral blood mononuclear cells (PBMCs) and are labor-
intensive and time-consuming.8 Recent studies have focused on
recombinant virus assays, based on the direct ampliﬁcation of
fragments from patient plasma. Some of these phenotypic
methods are based on single-cycle infection assays,9 whereas
others generate infectious viruses.10
A novel recombinant phenotypic assay is reported herein, in
which the recombinant viruses have the capacity of multiple cyclesTable 1
Basic information for 28 HIV-1 samples
Sample ID Gender Infection route 
BJ2006001 Male Heterosexual contact 
BJ2010001 Male MSM 
BJ2010002 Male MSM 
BJ2010003 Male MSM 
GD2005003 Male Blood transfusion 
GD2005004 Male Heterosexual contact 
GD2005006 Male Heterosexual contact 
GD2005025 Male IDU 
GD2005028 Female Blood transfusion 
GX2005002 Male Heterosexual contact 
GX2005016 Male Blood transfusion 
GX2005028 Male Heterosexual contact 
HN2002024 Male Blood transfusion 
HN2009001 Male Blood donation 
HN2010001 Male Blood donation 
HN2010002 Male Blood donation 
HN2010003 Female Blood transfusion 
HN2010004 Female Blood donation 
HN2010005 Female Blood donation 
NX2005012 Male Blood transfusion 
SC2009001 Male Occupational exposure 
SD2010001 Male MSM 
SD2013001 Male MSM 
SD2013005 Male MSM 
SD2013008 Male MSM 
SH2007052 Male Heterosexual contact 
SX2010001 Male Blood transfusion 
XJ2010001 Male MSM 
MSM, men who have sex with men; IDU, injection drug user.of replication. In this study, the susceptibility of the constructed
recombinant viruses to six ARV drugs was determined, and the
relationship between genotypic and recombinant virus phenotypic
analyses was evaluated.
2. Materials and methods
2.1. Plasma samples
Plasma specimens were collected from AIDS patients enrolled
in the China HIV drug resistance surveillance program. Plasma
samples were shipped on dry ice and stored at 80 8C until
analyzed. All samples collected in this study were successfully
isolated by PBMC co-culture. All patients provided written
informed consent and their basic personal and clinical information
was acquired by face-to-face interview. This study was approved
by the Ethics Committee of the Institutional Review Board of the
Academy of Military Medical Sciences.
2.2. Ampliﬁcation, sequencing, and HIV-1 subtype identiﬁcation
A nested PCR was employed to amplify the 2039-bp HIV-1 gag-
pol gene, which comprised the entire PR gene (codons 1–99) and
the former RT gene (codons 1–312). HIV-1 RNA was extracted from
200 ml plasma using the QIAamp Viral RNA Kit (Qiagen) and used
as a temple for one-step reverse transcriptase PCR (RT-PCR). The
RT-PCR primers were OUT5 50 TCAGAAGGAGCCACCCCACA 30 and
OUT3 50 CCCCTGCTTCTGTATTTCTGCTA 30. The one-step RT-PCR
reaction mixture (Takara) contained 5 mM MgCl2, 1 mM dNTP,
10 One Step RNA PCR Buffer (5 ml), 40 U RNase Inhibitor, 5 U AMV
RTase XL, 5 U AMV-Optimized Taq, 20 mM (each) primer, and 2 ml
of viral RNA, for a ﬁnal volume of 50 ml. Two microliters of the RT-
PCR mixture was used for the nested PCR, with 1.25 U Premix Ex
Taq (Takara) and 20 mM (each) primer (IN5: 50 GCGCATCCAGTG-
CATGCAGGGCCTATTG 30; IN3: 50 GCGGATGGGTCATAATACACTC-
CATGTACCGGTTC 30, respectively) combined to a total volume ofArea of origin Collection year Treatment
Beijing 2006 Naı¨ve
Beijing 2010 Naı¨ve
Beijing 2010 Naı¨ve
Beijing 2010 Naı¨ve
Guangdong 2005 Treated
Guangdong 2005 Treated
Guangdong 2005 Naı¨ve
Guangdong 2005 Naı¨ve
Guangdong 2005 Naı¨ve
Guangxi 2005 Naı¨ve
Guangxi 2005 Naı¨ve
Guangxi 2005 Naı¨ve
Henan 2002 Naı¨ve
Henan 2009 Treated
Henan 2010 Naı¨ve
Henan 2010 Naı¨ve
Henan 2010 Naı¨ve
Henan 2010 Naı¨ve
Henan 2010 Naı¨ve
Ningxia 2005 Naı¨ve
Sichuan 2009 Treated
Shandong 2010 Naı¨ve
Shandong 2013 Naı¨ve
Shandong 2013 Naı¨ve
Shandong 2013 Naı¨ve
Shanghai 2007 Naı¨ve
Shanxi 2010 Treated
Xinjiang 2010 Naı¨ve
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were carried out in a Biometra Thermocycler (Biometra).
The patient-derived PR-RT PCR products were electrophoresed
on a 1% (w/v) agarose gel, puriﬁed with the Wizard SV Gel and PCR
Clean-Up System (Promega), and directly sequenced. Subtypes
were determined by phylogenetic tree analysis of the PR–RT
fragments. The sequences were edited using ContigExpress
software and aligned using the BioEdit program. Alignments also
included the reference sequences representing HIV-1 genetic
circulating recombinant forms obtained from the HIV database.11
The phylogenetic tree was constructed using the maximum-
likelihood method by MEGA (Molecular Evolutionary Genetic
Analysis Software, version 5.1), and genetic distance reliability was
evaluated using the bootstrap test (1000 bootstrap replicates).Figure 1. Phenotypic and genetic drug susceptibility of 19 patient-drive recombinant vi
samples and the column height indicates the IC50 value. *Virus met the criteria of resista
polymorphisms corresponding to the resistant or hyper-susceptible samples.REGA12 and jpHMM (jumping proﬁle Hidden Markov Model) were
used to identify sequence subtypes that could not be determined
with MEGA. For each patient, drug resistance mutations were
determined by submitting the sequences to the Stanford Univer-
sity Network HIV-1 Database.13 Polymorphisms, which were
deﬁned as any change from the subtype B consensus sequence,14,15
were obtained and analyzed.
2.3. Generation and titration of recombinant viruses
Recombinant viruses were generated with a pNL4.3 vector, as
described previously.16 Brieﬂy, both the puriﬁed PCR products
derived from patients and the plasmids pNL4.3 were digested with
restriction enzymes SphI and AgeI (New England BioLabs),ruses and reference virus to six antiviral drugs. The columns represent the various
nce or hyper-susceptibility proposed in this article. Under the diagrams are various
Table 2
Fold-changes (FC) of 19 recombinant viruses compared with HIVpNL4.3
Sample ID Drugs (FC)a
AZT
3.0, 25b
3TC
3.0, 25
d4T
1.5, 3
ddI
1.5, 3
NVP
3.0, 25
EFV
3.0, 25
BJ2006001 1.08 1.42c 1.20 1.03 1.31 1.10
BJ2010001 1.11 0.56c 1.25 0.72 1.16 0.25
BJ2010002 1.24 1.04 1.11 0.96 1.29 1.15
BJ2010003 0.96 1.16 0.93 0.75 1.03 0.84
GD2005003 1.53 0.58c 0.77 0.66 7.39c,d 0.85
GD2005004 0.91 0.46c 1.43c 0.57 0.83 0.42
GD2005006 0.98 0.66 1.07 0.47c 0.49 0.45
GD2005028 1.06 0.33c,d 0.96 0.52c 2.05 0.90
HN2002024 1.20 0.51c 1.20 0.78 1.03 0.83
HN2010001 1.05 0.82 1.04 0.99 1.36 1.50
HN2010002 1.19 0.94 0.93 1.19 2.09 7.84c,d
HN2010003 1.16 0.52c 0.80 0.83 0.93 0.65
HN2010004 0.48 0.83 0.53c 0.46c 3.41 0.39
HN2009001 27.34c,d 17.08c,d 3.92c,d 4.38c,d 126.75c,d 26.73c,d
NX2005012 1.50 0.41c 1.19 0.74 2.80 0.45
SD2013001 1.45 0.68 1.13 1.32 1.10 1.09
SD2013005 1.36 0.58c 1.15 0.79 1.29 0.74
SD2013008 0.87 0.75 1.07 0.97 1.79 5.39c,d
XJ2010001 0.27c,d 0.28c,d 0.48c 0.35c,d 2.74 1.02
pNL4.3 1.00 1.00 1.00 1.00 1.00 1.00
AZT, zidovudine; 3TC, lamivudine; d4T, stavudine; ddI, didanosine; NVP,
nevirapine; EFV, efavirenz.
a The FC of recombinant viruses compared with HIVpNL4.3.
b Cut-off values.
c p < 0.05 when compared to the wild-type via least signiﬁcant difference (LSD)
test.
d The virus met the criteria of resistance or hyper-susceptibility proposed in this
article.
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pNL4.3-D(SphI-AgeI) vector, with PR (codons 1–99) and RT
(codons 1–312) deletions obtained via ligation reactions (New
England BioLabs) at 16 8C overnight and an insert-to-vector molar
ratio of 5:1. The 2.0-kb patient-derived PCR products replaced the
2.0-kb SphI–AgeI fragment of the pNL4.3 vector. Escherichia coli
DH5a competent cells (Tiangen) were transformed with the
ligation products, grown in liquid culture (Luria–Bertani (LB)
medium), and spread onto LB agar plates containing 100 mg/ml
ampicillin (TransGen Biotech). Positive clones were identiﬁed by
DNA sequencing and SphI and AgeI digestion. Exponentially
growing HEK293T cells (at a density of 4  105 cells/ml) were
seeded into 6-well plates containing 2 ml of growth medium and
incubated at 37 8C, 5% CO2 overnight. The next day, 293T cells were
transfected with the constructed plasmids using Lipofectamine
2000 (Life Technologies Corporation) according to the manufac-
turer’s instructions. Six hours post-transfection, 3 ml of fresh
DMEM (Dulbecco’s Modiﬁed Eagle Medium) supplemented with
10% FBS (Fetal Bovine Serum) was added. After 48 h, culture
supernatants containing the recombination viruses were har-
vested and stored at 80 8C until further use. Finally, sequencing
conﬁrmed that HIV-1 gag-pol sequences from the original plasma
samples and the corresponding recombinant viruses were nearly
identical. In order to obtain a higher recombinant viral titer, viruses
were propagated in MT-2 cells in RPMI 1640 medium supple-
mented with 10% FBS. The recombination viruses were serially
diluted 3-fold in 96-well plates and used to infect TZM-bl cells
(104 cells/well) in the presence of DMEM supplemented with
10% FBS. Viral replication was quantiﬁed 48 h post-infection by
measuring luciferase activity (relative luminescence units (RLU))
using the Bright-Glo Luciferase Assay System (Promega) in a multi-
well plate reader (Wallik 1420; Perkin Elmer). The Reed–Muench
method was used to calculate the 50% tissue culture infectious
dose (TCID50) of the constructed recombinant viruses.
2.4. Antiretroviral drugs
The ARV drugs used in this study and their sources were as
follows: zidovudine (ZDV, AZT) and lamivudine (3TC) from Sigma-
Aldrich Co.; didanosine (ddI), stavudine (d4T), nevirapine (NVP),
and efavirenz (EFV) from Shanghai Desano Chemical Pharmaceu-
tical Development Co., Ltd.
2.5. Drug susceptibility based on a multiple-cycle replication assay
Brieﬂy, triple serial dilutions spanning empirically determined
ranges for each drug were added to 384-well plates. Two hundred
recombinant viral TCID50s were used to infect TZM-bl cells (10
4
cells/well) containing pre-plated ARV drugs. At 48 h post-infection,
luciferase reporter gene expression was measured and the
percentage of inhibition was calculated according to the following
equation: [1  (luciferase activity in the presence of the drug/
luciferase activity in the absence of the drug)]  100. Drug
concentrations required to inhibit viral replication by 50% (IC50)
were calculated by (1) plotting the percentage inhibition of
luciferase activity versus the log10 drug concentration, and (2)
ﬁtting the inhibition curves to the data using non-linear regression
analysis and gaining a four parametric sigmoid dose–response
equation (GraphPad Prism, version 6.02). Three replicate determi-
nations were performed in duplicate plates for each concentration
of ARV drug. Mean IC50s were calculated using all replicates for
each virus and were expressed as the mean  standard deviation.
The results were expressed as fold-changes (FC), which reﬂect the
fold-change in the IC50 of a particular drug when tested with a
patient-derived recombinant virus relative to the IC50 of the same
drug when tested with a wild-type reference virus (HIVpNL4.3).Cut-off values for the different ARV drugs were used to establish
result classiﬁcations to include susceptibility, low–intermediate
resistance, and high resistance. For AZT, 3TC, EFV, and NVP, <3.0-
fold resistance indicated susceptibility, 3.0- to 25-fold indicated
low–intermediate resistance, and >25-fold indicated high resis-
tance. For d4T and ddI, a fold resistance of <1.5 was considered
susceptible, 1.5–3.0 was considered low–intermediate resistance,
and >3.0 was considered high resistance.17,18 Hyper-susceptibility
was deﬁned as a fold-change value <0.4.19 The virus was deﬁned as
resistant or hyper-susceptible if it met two criteria simultaneous-
ly: IC50 value signiﬁcantly higher or less than the wild-type
(p < 0.05) and a fold-change value outside the cut-off range.
2.6. Statistical analyses
To analyze the statistical signiﬁcance of differences in IC50 values
compared with the reference virus among the different samples,
multiple comparisons (least signiﬁcant difference test, LSD) were
completed with SPSS version 16.0 software (SPSS Inc., Chicago, IL,
USA). All analyses were performed using a two-tailed test; p-values
of <0.05 for the difference of IC50 compared with the wild-type
reference virus (HIVpNL4.3) were deﬁned as statistically signiﬁcant.
3. Results
3.1. Patient characteristics and genetic subtypes
Samples were obtained from 28 AIDS patients whose personal
information was examined carefully. These patients lived in
multiple districts and had become infected in various ways; all
had complete ART histories. They were from Beijing (n = 4),
Guangdong (n = 5), Guangxi (n = 3), Henan (n = 7), Ningxia (n = 1),
Shandong (n = 4), Shanghai (n = 1), Shanxi (n = 1), Sichuan (n = 1), and
Xinjiang (n = 1). The routes of HIV infection included men who have
sex with men (MSM; n = 8), heterosexual contact (n = 6), paid blood
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intravenous drug use (IDU) (n = 1). Of these patients, ﬁve were ART-
experienced (Table 1). Twenty-ﬁve (25/28) of the samples were
ampliﬁed and sequenced successfully. Nineteen gag-pol genetic
fragments originating from the corresponding plasma samples were
sub-cloned into the pNL4.3 vector, with homologous replication-
competent viruses obtained successfully; the identiﬁed viral genetic
subtypes included B/B0 (n = 11), CRF01_AE (n = 5), and CRF07_BC
(n = 3) (GenBank accession numbers KR030073 to KR030089).
3.2. Drug resistance mutations and genetic polymorphisms
All 19 of the fragment sequences for which recombinant
viruses were successfully constructed were translated and
compared with the consensus B sequences in the Stanford
University Network HIV-1 Database.13 Major drug resistanceFigure 2. Phenotypic drug susceptibility proﬁles from three patient-derived primary v
reference viral strain (blue) and the sample virus (red) are shown. The susceptibilities of
EFV). IC50 values were calculated by ﬁtting data to a sigmoid dose–response curve with v
between the sample and the reference.mutations including M41L, L210W, T215Y, K103N, and K238T
were identiﬁed in HN2009001, which was interpreted as having
high-level resistance to AZT, d4T, ddI, EFV, and NVP and low-level
resistance to 3TC. No primary or secondary drug resistance
mutations were found in the other 18 patients. However, amino
acid substitutions including V35T/I, T39K/D/R, K122E, D123S/E,
I135 V/L/R/T/M, S162C/Y, T200A/E, Q207A/E/K/S, R211S/KR, and
V245E/Q/I/T were found, with thumb sub-domain amino acid
substitutions A272P, K277R, K281R, T286A, E291D, V292I, and
I293 V also noted (Figure 1).
3.3. Drug susceptibility testing of recombinant viruses
Nineteen recombinant viruses were constructed successfully,
as described above, with a titration of 104–105 TCID50/ml.
Fold-changes of the 19 recombinant viruses relative to theiral isolates. Dose–response curves corresponding to the susceptible HIV-1pNL4.3
 (a, b) GD2005003, (c, d) HN2010002, and (e, f) SD2013008 to two NNRTIs (NVP and
ariable slope, and fold-change values were calculated as the IC50 ratio for each drug
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were calculated (Table 2). The recombinant viruses displayed a
variance in drug susceptibility for all six drugs tested.
In particular, sample HN2009001 was resistant to all drugs
tested. IC50 values (mean  standard deviation) for each drug were
as follows: AZT, 1.76  0.07 mM; 3TC, 8.08  0.24 mM; ddI, 28.23 
3.74 mM; d4T, 7.48  0.77 mM; NVP, 8.06  0.07 mM; EFV, 20.40 
3.49 nM. In comparison to the reference virus tested in parallel, the
inhibition curves were shifted toward higher drug concentrations for
the recombinant virus derived from HN2009001, with larger
reductions in susceptibilities to AZT (27.34-fold), 3TC (17.08-fold),
NVP (126.75-fold), and EFV (26.73-fold) exhibited. Less pronounced
reductions in susceptibilities to d4T (3.92-fold) and ddI (4.38-fold)
were also observed.
For the other samples, according to the criteria proposed above,
six of 18 viruses were resistant or hyper-susceptible to at least one
drug relative to the reference HIV-1 pNL4.3 strain. In detail, the
drug sensitivity of GD2005003, GD2005028, HN2010002, and
SD2013008 had changed signiﬁcantly to one kind of drug. Among
these samples, HN2010002 and SD2013008 exhibited a large
reduction in susceptibility to EFV (7.84- and 5.39-fold, respective-
ly), GD2005003 showed an intermediate resistance level to NVP
(7.39-fold, Figure 2), and a less pronounced elevation in
GD2005028 susceptibility to 3TC (3.0-fold) was also observed.
The susceptibility of XJ2010001 to the three nucleoside reverse
transcriptase inhibitors (NRTIs) AZT, 3TC, and ddI increased to 3.7-,
3.6-, and 2.9-fold, respectively (Figure 3).
3.4. Comparison of phenotypic and genotypic results
The phenotypic and genotypic results of the 19 recombinant
viruses in relation to the ARV drugs basically corresponded withFigure 3. Phenotypic drug susceptibility proﬁles of XJ2010001. Dose–response curves c
sample virus (red) are shown. XJ2010001 susceptibility to four NRTIs: (a) AZT, (b) 3TC, 
response curve with variable slope, and fold-change values were calculated as the IC50one another. In total, 114 drug resistance phenotypic results were
obtained and 97.4% agreed with the genotypic results. No
recognizable genotypic resistance-associated mutations were
noted, except in one sample. According to the phenotypic assay,
16 of the 19 samples were susceptible to the six drugs tested. For
the sample HN2009001 with major drug resistance mutations,
both the phenotypic and genotypic assays suggested that it was
resistant to all drugs tested. For the other samples, all phenotypic
and genotypic results obtained in relation to the NRTIs were in
agreement and all were susceptible to AZT, 3TC, d4T, and ddI, with
fold-changes of less than 3-, 3-, 1.5-, and 1.5-fold, respectively (the
cut-off value). When examining the phenotypic susceptibility
results to the non-nucleoside reverse transcriptase inhibitor
(NNRTIs), 7.9% (3/38) were inconsistent with the genotypic results.
4. Discussion
In the present study, recombinant viruses containing patient-
ampliﬁed PCR fragments encompassing entire protease and former
RT (positions 1 to 312) regions in wild-type pNL4.3 vectors were
constructed and harvested. Recombinant viral fold-changes in the
presence of six ARV drugs used widely in China were measured and
the relationships between phenotypic drug resistance and genetic
polymorphisms were evaluated.
No recognized genotypic resistance-associated mutations were
noted, except in the sample HN2009001, which had major drug
resistance mutations including M41L, L210W, T215Y, K103N, and
K238T. According to the clinical and statistical criteria, 16 of the
19 samples were susceptible to the six drugs tested. The phenotype
and genotype results basically corresponded with one another,
with a concordance rate of 97.4%.orresponding to the susceptible HIV-1pNL4.3 reference viral strain (blue) and the
(c) d4T, and (d) ddI. IC50 values were calculated by ﬁtting data to a sigmoid dose–
ratio for each drug between the sample and the reference.
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for the most part, there were some discrepancies between these
assays. According to the phenotypic assay, six of the 19 viruses had
signiﬁcant susceptibility alterations to at least one drug compared
with the reference HIV-1 pNL4.3 strain, while the genotypic assay
identiﬁed some amino acid substitutions. It has been widely
reported that HIV-1 genetic variability may inﬂuence ART efﬁcacy.
A polymorphism is deﬁned as a mutation that occurs frequently in
a virus not exposed to selective drug pressure. Drug resistance
mutations should be commonly recognized as causing or
contributing to resistance, should be non-polymorphic in untreat-
ed persons, and should be applicable to all HIV-1 subtypes.20 It has
been reported that naturally occurring polymorphisms have a
great inﬂuence on HIV-1 drug susceptibility. Furthermore,
polymorphisms can lead to ART failure in treatment-naı¨ve patients
and limit drug regimen efﬁcacy.21 The Stanford University
Network HIV-1 Database13 contains data from more than
420 published papers concerning mutations generated by viral
passage or site-directed mutagenesis.22 These additional muta-
tions are generally ignored, as they are often not shown in
genotyping reports. Substantial polymorphisms were observed in
the present study. No explicit explanations regarding the
polymorphisms were noted in the Stanford HIV-1 drug resistance
database.13 None of the mutations listed above was included in the
other two HIV-1 drug resistance databases (ANRS and Rege).23,24
Larger phenotypic studies are required to evaluate the impact of
these polymorphisms on ART susceptibility and viral ﬁtness in
order to improve current interpretation systems.
While some discrepancies were noted regarding the inﬂuences
of complicated amino acid substitutions, others may have been a
result of inappropriate cut-off values. Resistance is deﬁned on the
basis of assay-speciﬁc biological cut-off values originating from the
variation in susceptibility of treatment-naı¨ve individuals to
drugs.25,26 Harrigan et al. deﬁned the biological cut-off as the
mean fold-change plus two standard deviations among a popula-
tion of viruses from 1000 drug-naı¨ve patients.25 These papers have
shown that there is a large disparity in baseline values and that the
cut-off interval may be extended to some extent. The disparity in
HIV-1 susceptibility indicates a need to further investigate the
clinical effectiveness of ART in certain individuals.
In conclusion, this study presents a new and useful tool for
assessing drug susceptibility to ARV drugs, permitting the
quantitation of the level of resistance. In comparison to traditional
phenotypic assays, it is an affordable and rapid in-house assay for
the evaluation of susceptibility to ARV drugs of clinical viruses and
the mutation proﬁle of antiviral agents that are promising for
further development.
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